Korro Bio, Inc. (KRRO)

Korro Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-88.42	-83.58	-81.17	-58.03	-21.96
Depreciation & Amortization	4.88	3.57	3.63	2.51	1.6
Loss (Gain) From Sale of Assets	0.44	0.36	0.07	-	0.01
Loss (Gain) From Sale of Investments	-1.09	-1.78	-0.08	-0.15	0.02
Stock-Based Compensation	6.94	4.46	2.38	1.14	0.81
Other Operating Activities	0.69	3.31	3.61	1.51	-13.47
Change in Accounts Receivable	-0.82	-1.7	-	-	-
Change in Accounts Payable	-2.28	-1.34	3.1	1.76	0.06
Change in Unearned Revenue	8.16	9.43	-	-	-0.69
Change in Other Net Operating Assets	3.15	7.2	1.18	-2.39	1.53
Operating Cash Flow	-68.35	-60.07	-67.28	-53.65	-32.09
Capital Expenditures	-1.89	-17.9	-7.84	-5.21	-4.45
Sale of Property, Plant & Equipment	-	-	-	-	0.01
Investment in Securities	28.2	-105.45	19	16.27	-35.07
Investing Cash Flow	26.31	-123.35	11.16	11.06	-39.5
Issuance of Common Stock	1.24	69.36	154.55	0.06	0.03
Other Financing Activities	-	-	-12.25	-0.04	-0.03
Financing Cash Flow	1.24	69.36	187.76	0.02	115.95
Foreign Exchange Rate Adjustments	-0.02	-0	-	-	-
Net Cash Flow	-40.82	-114.07	131.64	-42.57	44.35
Free Cash Flow	-70.24	-77.98	-75.12	-58.86	-36.54
Free Cash Flow Margin	-952.92%	-3433.55%	-	-	-
Free Cash Flow Per Share	-7.49	-8.74	-49.12	-230.65	-8.22
Cash Income Tax Paid	0.1	0.14	0.03	0.01	-
Levered Free Cash Flow	-41.2	-69.99	-47.69	-38.2	-
Unlevered Free Cash Flow	-41.2	-69.99	-47.69	-38.2	-
Change in Working Capital	8.2	13.59	4.28	-0.63	0.9

Updated Nov 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q